Isoastragaloside I improves hyperglycaemia and increases β‐cell mass in mice
Diabetic Medicine · 2026
DOI: 10.1111/dme.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Ankang Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Utilization of Woody Oil Resource, Heilongjiang Key Laboratory of Plant Bioactive Substance Biosynthesis and Utilization, Mol…. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Hyperglycemia, Diabetes Mellitus, Experimental, Saponins. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Aims
This study aims to investigate the effects of isoastragaloside I (IAS‐I) on improving diabetic symptoms and its impact on endogenous β‐cell mass, and further explore the origins of increased β‐cells.
Methods
Healthy and diabetic mice received IAS‐I treatment (5 or 0.5 mg/kg, respectively) via tail veil injection. The blood glycaemic control, body weight, and glucose/insulin tolerance were evaluated. Safety was assessed via complete blood count and histopathological analysis. Uniformly sampled pancreatic sections (spanning the entire pancreas) were immunohistochemically stained for β‐cells, imaged, and analysed by point‐counting morphometry to estimate β‐cell mass. Furthermore, SOX9‐CreER T2 ; R26‐LSL‐tdTomato mice were used to trace the pancreatic ductal cell, and conduct multiplex immunohistochemistry to explore the conversion of pancreatic ductal cells into β‐cells.
Results
In both healthy and diabetic mice, IAS‐I could increase the β‐cell mass; especially 0.5 mg/kg IAS‐I significantly increased the small islet mass. Using lineage tracing, we demonstrated that IAS‐I promoted the generation of β‐cells from ductal cells. We also found that IAS‐I could improve the fasting blood glucose and insulin resistance in diabetic mice, and the safety of IAS‐I in vivo had also been preliminarily demonstrated.
Conclusion
Our results suggest that IAS‐I increases β‐cell mass and promotes the formation of β‐cells from pancreatic ductal cells in vivo. It is also speculated to possess islet‐protective activity. These findings provide insight into the potential application of Astragalus membranaceus monomers in diabetic treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Utilization of Woody Oil Resource, Heilongjiang Key Laboratory of Plant Bioactive Substance Biosynthesis and Utilization, Molecular Cell Biology Laboratory, College of Life Science, Northeast For…
ORCID-Profile: Miao Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Pan, A., Wu, H., Wang, Q., Zhang, S., Chen, Y., Zhang, T., Liu, M., & Teng, C. B. (2026). Isoastragaloside I improves hyperglycaemia and increases β‐cell mass in mice. Diabetic Medicine. https://doi.org/10.1111/dme.70162
Vancouver
Pan A, Wu H, Wang Q, Zhang S, Chen Y, Zhang T, et al. Isoastragaloside I improves hyperglycaemia and increases β‐cell mass in mice. Diabetic Medicine. 2026. doi:10.1111/dme.70162
BibTeX
@article{Pan2026,
author = {Pan, Ankang and Wu, Huan and Wang, Qian and Zhang, Shuting and Chen, Yuhan and Zhang, Tongsheng and Liu, Miao and Teng, Chun-Bo},
title = {Isoastragaloside I improves hyperglycaemia and increases β‐cell mass in mice},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70162}
}
EUVIMED